Few analysts foresaw the disappointing results and profit forecast that sent Boston Scientific Corp.’s shares plummeting nearly 20% this week. Even fewer have given up on their bullish calls since. It ...

A general view of a Boston Scientific advertisement during a women's college lacrosse game between the Notre Dame Fighting Irish and the Boston College Eagles on March 16, 2024 at Alumni Stadium in ...

The Boston Scientific Analyst: Analyst Mike Matson maintained a Buy rating, but slashed the price target from $121 to $97. The Boston Scientific Thesis: The company reported revenue of $5.286 billion ...

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income ...

Despite growing sales and adjusted EPS by 16% and 14% in Q4 -- easily beating Wall Street’s estimates -- Boston Scientific stock dropped 18% on Wednesday due to “weak” guidance. More specifically, the ...

Boston Scientific grew sales and adjusted earnings per share by 16% and 14% in the fourth quarter. However, the company's guidance underwhelmed the market. Ultimately, Boston Scientific's earnings ...

Boston Scientific’s fourth-quarter profit and sales climbed but the medical-device maker issued a soft forecast for the year, sending shares down in premarket trading. The company logged earnings of ...

Feb 4 (Reuters) - Boston Scientific (BSX.N), opens new tab on Wednesday reported lower-than-expected quarterly sales in its key electrophysiology division, dragging the medical device maker's shares ...

Boston Scientific (BSX) lost ~9% in the premarket on Wednesday after the MedTech giant indicated an underwhelming outlook for 2026 with its Q4 2025 results, which, however, beat Street forecasts ...

The company's earnings came in at $672 million, or $0.45 per share. This compares with $566 million, or $0.38 per share, last year. Excluding items, Boston Scientific Corp reported adjusted earnings ...